RAIN — Rain Oncology Income Statement
0.000.00%
HealthcareMicro Cap
- $44.03m
- -$33.29m
Annual income statement for Rain Oncology, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
Standards: | USG | USG | USG | USG |
Status: | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | ||||
Research And Development | ||||
Unusual Expense / Income | ||||
Total Operating Expenses | 10.8 | 19 | 51.5 | 77.1 |
Operating Profit | -10.8 | -19 | -51.5 | -77.1 |
Total Net Non Operating Interest Income / Expense | ||||
Other Net Non Operating Costs | ||||
Net Income Before Taxes | -10.9 | -21.1 | -51.4 | -75.7 |
Provision for Income Taxes | ||||
Net Income After Taxes | -10.9 | -21.1 | -51.4 | -75.7 |
Net Income Before Extraordinary Items | ||||
Net Income | -10.9 | -21.1 | -51.4 | -75.7 |
Adjustments to Net Income | ||||
Income Available to Common Shareholders Excluding Extraordinary Items | ||||
Income Available to Common Shareholders Including Extraordinary Items | ||||
Diluted Net Income | -10.9 | -21.1 | -51.4 | -75.7 |
Diluted Weighted Average Shares | ||||
Basic EPS Including Extraordinary Items | ||||
Diluted EPS Including Extraordinary Items | ||||
Diluted EPS Excluding Extraordinary Items | ||||
Normalised Income Before Taxes | ||||
Normalised Income After Taxes | ||||
Normalised Income Available to Common Shareholders | ||||
Diluted Normalised EPS | -0.42 | -0.613 | -2.65 | -2.71 |
Dividends per Share |